<DOC>
	<DOCNO>NCT00629213</DOCNO>
	<brief_summary>The aim study analyse independent joint effect component metabolic syndrome ( MetS ) incidence diabetes people impair glucose tolerance ( IGT ) ass effect acarbose MetS status . Double-blind placebo control trial , 1,368 patient , follow-up time 3.3 year . MetS ATP III definition fast plasma glucose â‰¥ 6.1 mmol/l limit impair fast glucose ( IFG ) .</brief_summary>
	<brief_title>Metabolic Syndrome Risk Factor IGT : STOP-NIDDM Trial</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>High risk population Age 40 70 yr . BMI &gt; 25 &lt; 40 ; FPG &gt; 5.5 mmol/l &lt; 7.8 mmol/l ; IGT OGGT Known type 2 diabetes Drug intake affect glucose tolerance Any cardiovascular event within last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>prevention ,</keyword>
	<keyword>type 2 diabetes ,</keyword>
	<keyword>metabolic syndrome ,</keyword>
	<keyword>acarbose treatment</keyword>
</DOC>